Whitehawk Therapeutics, Inc.
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -200.6% | -152.5% | -367.1% | -148.2% | -217.5% | -207.9% | -166.0% | – | – | – | – | – | – | |
| 0.7% | 0.7% | 0.9% | 0.8% | 0.7% | 0.6% | 0.8% | – | – | – | – | – | – | |
| 51.2% | 49.2% | 67.0% | 45.9% | 35.5% | 25.6% | 23.5% | – | – | – | – | – | – | |
| 0.1% | -15.4% | 37.5% | 5.0% | 7.9% | 11.5% | 10.3% | – | – | – | – | – | – | |
| 18.4% | 12.9% | 13.8% | 8.8% | 2.6% | 2.6% | 7.7% | – | – | – | – | – | – | |
| 212.6% | 57.7% | 197.2% | -57.8% | 70.5% | 181.4% | 1,616.5% | – | – | – | – | – | – | |
| -1.3% | 1.3% | -0.2% | 1.4% | 0.0% | 0.7% | 1,332.4% | – | – | – | – | – | – | |
| 10.8% | -93.5% | -170.1% | -204.6% | -147.0% | -25.8% | 2,782.9% | – | – | – | – | – | – | |
| -219.0% | -165.3% | -380.9% | -157.0% | -220.1% | -210.5% | -173.8% | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.